Akebia Therapeutics (AKBA) said Thursday that its Vafseo drug for anemia related to chronic kidney disease has been granted Transitional Drug Add-On Payment Adjustment, or TDAPA, reimbursement, effective Jan. 1, 2025, by the Centers for Medicare and Medicaid Services.
Vafseo is expected to be available in the market in January, according to Akebia. It was approved by the US Food and Drug Administration in March to treat anemia caused by chronic kidney disease in adults.
The TDAPA program provides reimbursement for Vafseo for the next two years on top of the bundled rate under the End-Stage Renal Disease prospective payment system, Akebia said.
The company also said it received a Level II Healthcare Common Procedure Coding System code for Vafseo that will be used by dialysis organizations for billing for Medicare enrollees.
Price: 1.3000, Change: +0.02, Percent Change: +1.56
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.